What is Claimed is:

- 1. A composition for topical or transdermal administration comprising:
 - (i) a bioactive agent; and
 - (ii) Gilsonite oil.
- 2. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.
- 3. The composition of claim 2, further comprising a pharmaceutically acceptable additive selected from the group consisting of excipients, preservatives, antioxidants, fragrances, emulsifiers, dyes, adhesives, polymers and additional penetration enhancers.
 - 4. The composition of claim 1, wherein the bioactive agent is present in about 0.0001% to about 50% by weight.
- The composition of claim 1, wherein the Gilsonite oil is present in about 0.0001% to about 50% by weight.
 - 6. A penetration-enhancing system comprising,
 - (i) Gilsonite oil; and
 - (ii) a pharmaceutically acceptable carrier.
- 7. The penetration-enhancing system of claim 6, further comprising a pharmaceutically acceptable carrier.

- 8. The penetration-enhancing system of claim 7, further comprising a pharmaceutically acceptable additive selected from the group consisting of excipients, preservatives, antioxidants, fragrances, emulsifiers, dyes, adhesives, polymers and additional penetration enhancers.
- 5 9. The penetration-enhancing system of claim 6, wherein the bioactive agent is present in about 0.0001% to about 50% by weight.
 - 10. The penetration-enhancing system of claim 6, wherein the Gilsonite oil is present in about 0.0001% to about 50% by weight.
- 11. A composition for topical or transdermal application with enhancedpenetration comprising:
 - (a) a bioactive agent; and
 - (b) a penetration enhancing system comprising;
 - (i) Gilsonite oil; and
 - (ii) a pharmaceutically acceptable carrier.

- 12. The composition for topical or transdermal application of claim 11, wherein the pharmaceutically acceptable carrier is selected from the group consisting of oils, lotions, gels, creams, and ointments.
- The composition for topical or transdermal application of claim
 11, wherein the pharmaceutically acceptable carrier is suitable for use with transdermal patches.

- 14. The composition for topical or transdermal application of claim 12, further comprising a pharmaceutically acceptable additive selected from the group consisting of excipients, preservatives, antioxidants, fragrances, emulsifiers, dyes, adhesives, polymers and additional penetration enhancers.
- 15. 5 The composition for topical or transdermal application of claim 12, wherein the bioactive agent is present in about 0.0001% to about 50% by weight.
 - 16. The composition for topical or transdermal application of claim 12, wherein the Gilsonite oil is present in about 0.0001% to about 50% by weight.
- 17. A method for enhancing the penetration of a bioactive agent 10 through the skin of a human or warm-blooded animal which comprises applying to a body surface:
 - (a) a bioactive agent; and

- (b) a penetration-enhancing system comprising,
 - (i) Gilsonite oil; and
 - (ii) a pharmaceutically acceptable carrier.
- 18. The method for enhancing the penetration of claim 17, wherein the pharmaceutically acceptable carrier is selected from the group consisting of oils, lotions, gels, creams, adhesives and ointments.
- 19. The method for enhancing the penetration of claim 17, wherein the pharmaceutically acceptable carrier is suitable for use with transdermal 20 patches.

Attorney Docket No.: 033292-004

- 20. The method for enhancing the penetration of claim 18, further comprising a pharmaceutically acceptable additive selected from the group consisting of excipients, preservatives, antioxidants, fragrances, emulsifiers, dyes, adhesives, polymers and additional penetration enhancers.
- 5 21. The method for enhancing the penetration claim 18, wherein the bioactive agent is present in about 0.0001% to about 50% by weight.
 - 22. The method for enhancing the penetration of claim 18, wherein the Gilsonite oil is present in about 0.0001% to about 50% by weight.
- 23. A method for delivering a bioactive agent transdermally, which method comprises administering to the skin a composition comprising
 - (i) a bioactive agent; and
 - (ii) Gilsonite oil.
- 24. The method for delivering a bioactive agent transdermally of claim 23, further comprising a pharmaceutically acceptable carrier selected from the group consisting of oils, lotions, gels, creams, and ointments.
 - 25. The method for delivering a bioactive agent transdermally of claim 24, wherein the pharmaceutically acceptable carrier is suitable for use with transdermal patches.

Attorney Docket No.: 033292-004

26. The method for delivering a bioactive agent transdermally of claim 24, further comprising a pharmaceutically acceptable additive selected from the group consisting of excipients, preservatives, antioxidants, fragrances, emulsifiers, dyes, adhesives, polymers and additional penetration enhancers.

- 5 27. The method for delivering a bioactive agent transdermally of claim 24, wherein the bioactive agent is present in about 0.0001% to about 50% by weight.
 - 28. The method for delivering a bioactive agent transdermally of claim 24, wherein the Gilsonite oil is present in about 0.0001% to about 50% by weight.

10

- 29. A method for making a composition for transdermal delivery of a bioactive agent comprising mixing the bioactive agent and a Gilsonite oil in proportions effective to provide a composition for the desired use.
- 30. The method for making a composition for transdermal delivery of claim 29, further comprising mixing in a pharmaceutically acceptable carrier selected from the group consisting of oils, lotions, gels, creams, adhesives and ointments.
- The method of claim 30, further comprising mixing in at least one pharmaceutically acceptable penetration-enhancing additives, excipients, preservatives, antioxidants, fragrances, emulsifiers, or dyes.

Attorney Docket No.: 033292-004

- 32. A device for topical or transdermal administration of a pharmaceutical composition comprising:
 - (a) an applicator adapted for placement on the skin or nail; and
 - (b) a pharmaceutical composition comprising:
 - (i) a Gilsonite oil; and

- (ii) a bioactive agent.
- 33. The device of claim 32, wherein the device is a transdermal patch, strip or a container.
- 34. The device of claim 33, wherein the device is a transdermal patch and the pharmaceutically acceptable carrier is suitable for use with transdermal patches.
 - 35. The device of claim 33 wherein the bioactive agent is present in about 0.0001% to about 50% by weight and the Gilsonite oil is present in about 0.0001% to about 50% by weight.
- 15 36. A method of making a device for drug administration comprising providing an applicator adapted for placement on the skin or nail and incorporating into the applicator a composition comprising a Gilsonite oil and a bioactive agent.